JAC Advance Access originally published online on August 18, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(4):832-835; doi:10.1093/jac/dkh405
JAC vol.54 no.4 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6
1 Department of Medicine, Harbor-UCLA Research and Education Institute, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502; 2 David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA
* Corresponding author. Tel: +1-310-222-3813; Fax: +1-310-782-2016; Email: bjs{at}humc.edu
Objectives: We sought to determine if vitamin B6 therapy would reverse linezolid-associated cytopenias and/or peripheral neuropathy.
Patients and methods: We have recently treated two patients with disseminated Mycobacterium abscessus infections with prolonged (
9 month) courses of linezolid. Both patients developed cytopenias related to linezolid, and one patient also developed peripheral neuropathy. Because continuing linezolid therapy was required, we administered vitamin B6 (50 mg orally once a day) in an attempt to mitigate the associated cytopenias.
Results: The cytopenias in both patients reversed following administration of vitamin B6, and stabilized during prolonged linezolid therapy, although the peripheral neuropathy did not.
Conclusions: Vitamin B6 treatment may be useful to prevent or modify the course of linezolid-associated cytopenias. More formal and rigorous study of vitamin B6 therapy in patients receiving prolonged courses of linezolid is warranted.
Keywords: pyridoxine , anaemia , thrombocytopenia , Mycobacteria , deficiency
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Youssef, R. Hachem, R. F. Chemaly, J. Adachi, J. Ying, K. Rolston, and I. Raad The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer J. Antimicrob. Chemother., February 1, 2008; 61(2): 421 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Z Jodlowski, I. Melnychuk, and J. Conry Linezolid for the Treatment of Nocardia spp. Infections Ann. Pharmacother., October 1, 2007; 41(10): 1694 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garrabou, A. Soriano, S. Lopez, J. P. Guallar, M. Giralt, F. Villarroya, J. A. Martinez, J. Casademont, F. Cardellach, J. Mensa, et al. Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia Antimicrob. Agents Chemother., March 1, 2007; 51(3): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fortun, P. Martin-Davila, E. Navas, M. J. Perez-Elias, J. Cobo, M. Tato, E. G.-G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno Linezolid for the treatment of multidrug-resistant tuberculosis J. Antimicrob. Chemother., July 1, 2005; 56(1): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Zivkovic and D. Lacomis Severe sensory neuropathy associated with long-term linezolid use Neurology, March 8, 2005; 64(5): 926 - 927. [Full Text] [PDF]
|
|